SEC F	orm 4
-------	-------

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average bu	urden								

Estimated average burden	
hours per response:	0.5

1. Name and Address of Reporting Person* <u>Medeiros David Jeffrey</u>	2. Issuer Name and Ticker or Trading Symbol <u>QUESTCOR PHARMACEUTICALS INC</u> [QCOR]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below)
(Last) (First) (Middle) 1300 NORTH KELLOGG DRIVE SUITE D	3. Date of Earliest Transaction (Month/Day/Year) 10/28/2011	Senior VP, Pharm. Operations
(Street) ANAHEIM CA 92807 (City) (State) (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

······································											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	10/28/2011		S		147,756	D	\$41.55(1)	62,660	D		
Common Stock	10/31/2011		S		55,221	D	\$42.26(7)	7,439	D		
Common Stock	10/31/2011		М		4,002	A	\$0.6	11,441	D		
Common Stock	10/31/2011		М		3,246	A	\$0.89	14,687	D		
Common Stock	10/31/2011		S		7,248	D	\$42.65(2)	7,439	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) (Disp of (I	osed)) tr. 3, 4	Expiration Date (Month/Day/Year) sed 3, 4		te Amount of		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy) ⁽³⁾	\$0.6	10/31/2011		М			4,002	(4)	12/10/2013	Common Stock	4,002	\$0	18,241	D	
Stock Option (Right to Buy) ⁽⁵⁾	\$0.89	10/31/2011		М			3,246	(6)	02/23/2014	Common Stock	3,246	\$0	26,754	D	

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$41.40-\$41.75, inclusive. The reporting person undertakes to provide Questcor Pharmaceuticals, Inc., any security holder of Questcor Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 1 of the Form 4.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$42.65-\$42.67, inclusive. The reporting person undertakes to provide Questcor Pharmaceuticals, Inc., any security holder of Questcor Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 2 of the Form 4.

3. Incentive Stock option granted under the Questcor Pharmaceuticals, Inc. 1992 Employee Stock Option Plan on December 11, 2003.

4. The option was fully vested and exercisable as of December 11, 2007.

5. Incentive Stock option granted under the Questcor Pharmaceuticals, Inc. 1992 Employee Stock Option Plan on February 24, 2004.

6. The option was fully vested and exercisable as of February 24, 2008.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$41.94-\$42.50, inclusive. The reporting person undertakes to provide Questcor Pharmaceuticals, Inc., any security holder of Questcor Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 7 of the Form 4.

/s/ David Jeffrey Medeiros 1

** Signature of Reporting Person Date

11/01/2011

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.